Thema: Presse: Agreement for Wafer with Link Pharmaceuticals
Presse: Agreement for Wafer with Link Pharmaceuticals
Anne[a]
04.06.2004 11:18:58
Marketing and Distribution Agreement for GLIADEL Wafer with Link Pharmaceuticals
Guilford Pharmaceuticals, Inc. announced today that it has granted exclusive rights to Link Pharmaceuticals Ltd. to market, sell and distribute its proprietary brain cancer therapy, GLIADEL® Wafer (polifeprosan 20 with carmustine implant) in Germany, France, Benelux, Austria and Switzerland. These countries are in addition to the existing contract with Link for the United Kingdom. Link will be responsible for obtaining pricing approvals for GLIADEL® in each of the countries covered under the agreement. Guilford received $500,000 at signing and may receive additional milestone payments totaling up to $2 million. If GLIADEL® is approved for initial surgery in France and Germany, Guilford will receive a $750,000 milestone payment. GLIADEL® is currently approved for use in 13 countries outside of the United States and Canada to treat recurrent glioblastoma multiforme, an aggressive form of primary malignant brain cancer.
"Guilford´s second agreement with Link expands our network of international partners in major global healthcare markets and is a key component of our ability to increase sales of GLIADEL® outside the United States," stated Craig R. Smith, M.D., Chairman, President and Chief Executive Officer of Guilford. "The agreement is particularly important as we continue our discussions with European regulatory authorities to seek an expanded indication for GLIADEL® during initial surgery for high grade malignant glioma." In February 2003, Guilford received approval in the United States for expanded use of GLIADEL® in newly diagnosed patients with high-grade malignant glioma as an adjunct to surgery and radiation. GLIADEL® is also approved in Canada for initial surgery in the treatment of high-grade malignant glioma and for use in recurrent glioblastoma multiforme."
"Acquiring GLIADEL® for 7 additional Northern European countries is a major step for Link," said Steve Mountain, CEO and Managing Director, Link Pharmaceuticals. "GLIADEL® is a strategic product in our UK portfolio of oncology and palliative therapies and now we are looking forward to Link Europe launching GLIADEL® and achieving outstanding success in these important countries."
Guilford Pharmaceuticals
BALTIMORE, May 17 -- 2004
Guilford Pharmaceuticals, Inc. announced today that it has granted exclusive rights to Link Pharmaceuticals Ltd. to market, sell and distribute its proprietary brain cancer therapy, GLIADEL® Wafer (polifeprosan 20 with carmustine implant) in Germany, France, Benelux, Austria and Switzerland. These countries are in addition to the existing contract with Link for the United Kingdom. Link will be responsible for obtaining pricing approvals for GLIADEL® in each of the countries covered under the agreement. Guilford received $500,000 at signing and may receive additional milestone payments totaling up to $2 million. If GLIADEL® is approved for initial surgery in France and Germany, Guilford will receive a $750,000 milestone payment. GLIADEL® is currently approved for use in 13 countries outside of the United States and Canada to treat recurrent glioblastoma multiforme, an aggressive form of primary malignant brain cancer.
"Guilford´s second agreement with Link expands our network of international partners in major global healthcare markets and is a key component of our ability to increase sales of GLIADEL® outside the United States," stated Craig R. Smith, M.D., Chairman, President and Chief Executive Officer of Guilford. "The agreement is particularly important as we continue our discussions with European regulatory authorities to seek an expanded indication for GLIADEL® during initial surgery for high grade malignant glioma." In February 2003, Guilford received approval in the United States for expanded use of GLIADEL® in newly diagnosed patients with high-grade malignant glioma as an adjunct to surgery and radiation. GLIADEL® is also approved in Canada for initial surgery in the treatment of high-grade malignant glioma and for use in recurrent glioblastoma multiforme."
"Acquiring GLIADEL® for 7 additional Northern European countries is a major step for Link," said Steve Mountain, CEO and Managing Director, Link Pharmaceuticals. "GLIADEL® is a strategic product in our UK portfolio of oncology and palliative therapies and now we are looking forward to Link Europe launching GLIADEL® and achieving outstanding success in these important countries."
Guilford Pharmaceuticals
BALTIMORE, May 17 -- 2004
Anne[a]
